1kbq Citations

Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches.

Biochemistry 40 15135-42 (2001)
Cited: 50 times
EuropePMC logo PMID: 11735396

Abstract

We report the characterization of 5-methoxy-1,2-dimethyl-3-[(4-nitrophenoxy)methyl]indole-4,7-dione (ES936) as a mechanism-based inhibitor of NQO1. Inactivation of NQO1 by ES936 was time- and concentration-dependent and required the presence of a pyridine nucleotide cofactor consistent with a need for metabolic activation. That ES936 was an efficient inhibitor was demonstrated in these studies by the low partition ratio (1.40 +/- 0.03). The orientation of ES936 in the active site of NQO1 was examined by X-ray crystallography and found to be opposite to that observed for other indolequinones acting as substrates. ES936 was oriented in such a manner that, after enzymatic reduction and loss of a nitrophenol leaving group, a reactive iminium species was located in close proximity to nucleophilic His 162 and Tyr 127 and Tyr 129 residues in the active site. To determine if ES936 was covalently modifying NQO1, ES936-treated protein was analyzed by electrospray ionization liquid chromatography/mass spectrometry (ESI-LC/MS). The control NQO1 protein had a mass of 30864 +/- 6 Da (n = 20, theoretical, 30868.6 Da) which increased by 217 Da after ES936 treatment (31081 +/- 7 Da, n = 20) in the presence of NADH. The shift in mass was consistent with adduction of NQO1 by the reactive iminium derived from ES936 (M + 218 Da). Chymotryptic digestion of the protein followed by LC/MS analysis located a tetrapeptide spanning amino acids 126-129 which was adducted with the reactive iminium species derived from ES936. LC/MS/MS analysis of the peptide fragment confirmed adduction of either Tyr 127 or Tyr 129 residues. This work demonstrates that ES936 is a potent mechanism-based inhibitor of NQO1 and may be a useful tool in defining the role of NQO1 in cellular systems and in vivo.

Articles - 1kbq mentioned but not cited (5)

  1. Exploring off-targets and off-systems for adverse drug reactions via chemical-protein interactome--clozapine-induced agranulocytosis as a case study. Yang L, Wang K, Chen J, Jegga AG, Luo H, Shi L, Wan C, Guo X, Qin S, He G, Feng G, He L. PLoS Comput Biol 7 e1002016 (2011)
  2. A mechanistic and structural analysis of the inhibition of the 90-kDa heat shock protein by the benzoquinone and hydroquinone ansamycins. Reigan P, Siegel D, Guo W, Ross D. Mol Pharmacol 79 823-832 (2011)
  3. Identified the Synergistic Mechanism of Drynariae Rhizoma for Treating Fracture Based on Network Pharmacology. Lin H, Wang X, Wang L, Dong H, Huang P, Cai Q, Mo Y, Huang F, Jiang Z. Evid Based Complement Alternat Med 2019 7342635 (2019)
  4. A direct interaction between NQO1 and a chemotherapeutic dimeric naphthoquinone. Pidugu LS, Mbimba JC, Ahmad M, Pozharski E, Sausville EA, Emadi A, Toth EA. BMC Struct Biol 16 1 (2016)
  5. Understanding the polypharmacological anticancer effects of Xiao Chai Hu Tang via a computational pharmacological model. Zheng CS, Wu YS, Bao HJ, Xu XJ, Chen XQ, Ye HZ, Wu GW, Xu HF, Li XH, Chen JS, Liu XX. Exp Ther Med 7 1777-1783 (2014)


Reviews citing this publication (3)

  1. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Wondrak GT. Antioxid Redox Signal 11 3013-3069 (2009)
  2. DT-diaphorase: a target for new anticancer drugs. Danson S, Ward TH, Butler J, Ranson M. Cancer Treat Rev 30 437-449 (2004)
  3. Natural and synthetic quinones and their reduction by the quinone reductase enzyme NQO1: from synthetic organic chemistry to compounds with anticancer potential. Colucci MA, Moody CJ, Couch GD. Org Biomol Chem 6 637-656 (2008)

Articles citing this publication (42)



Related citations provided by authors (2)